arsenic has been researched along with homoharringtonine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, K; Jiang, G; Tang, T | 1 |
| Alvarez, RH; Cortes, JE; Giles, F; Kantarjian, HM; O'Brien, SM; Talpaz, M | 1 |
| Aleskog, A; Barbany, G; Bengtsson, M; Björnberg, A; Höglund, M; Larsson, R; Lindhagen, E; Olsson-Strömberg, U; Simonsson, B | 1 |
| Meng, H; Qian, W; Shao, K; Yang, C; Yang, X; Ye, X; Zhou, Y | 1 |
| Chuah, C; Melo, JV | 1 |
| Cortes, J; Giles, F | 1 |
| Cao, JJ; Chen, D; Chen, LG; Du, XH; Fan, Z; Li, SY; Lin, L; Liu, XH; Ma, JX; Pei, RZ; Sha, KY; Shi, XW; Tang, SH; Wu, JY; Ye, PP; Zhang, BB; Zhang, PS; Zhuang, XX | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 1 |
| Chen, XH; Qian, WB; Zhou, XJ; Zhou, YH | 1 |
| Iacoboni, G; Montesinos, P; Sanz, MA | 1 |
4 review(s) available for arsenic and homoharringtonine
| Article | Year |
|---|---|
Investigational strategies in chronic myelogenous leukemia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Cancer Vaccines; DNA Methylation; Enzyme Inhibitors; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Research; Treatment Outcome | 2004 |
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Topics: Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Amplification; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2008 |
New agents in chronic myelogenous leukemia.
Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Cytosine; Dioxolanes; Farnesyltranstransferase; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Vaccination | 2003 |
Conventional induction and post-remission therapy in APL: have we arrived?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Mitoxantrone; Multicenter Studies as Topic; Oxides; Remission Induction; Tretinoin | 2014 |
1 trial(s) available for arsenic and homoharringtonine
| Article | Year |
|---|---|
[Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2013 |
5 other study(ies) available for arsenic and homoharringtonine
| Article | Year |
|---|---|
[Drug resistance of acute promyelocytic leukemia (APL) to all-trans retinoic acid (ATRA) and its reversion].
Topics: Alprostadil; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Cell Survival; Drug Interactions; Drug Resistance; Harringtonines; HL-60 Cells; Homoharringtonine; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Promyelocytic, Acute; Oxides; Recombinant Proteins; Tretinoin | 2000 |
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Cytarabine; Daunorubicin; Feasibility Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; In Vitro Techniques; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Vincristine | 2006 |
Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Harringtonines; Homoharringtonine; Humans; Male; Melphalan; Multiple Myeloma; Oxides; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vincristine; Vindesine | 2007 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
[Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Caspase 3; Caspase 9; Cell Line, Tumor; Harringtonines; Homoharringtonine; Humans; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2 | 2013 |